91,900 Shares in OraSure Technologies, Inc. (NASDAQ:OSUR) Purchased by Virtus Investment Advisers Inc.

Virtus Investment Advisers Inc. bought a new stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 91,900 shares of the medical instruments supplier’s stock, valued at approximately $392,000. Virtus Investment Advisers Inc. owned approximately 0.12% of OraSure Technologies as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in OSUR. AXA S.A. grew its stake in shares of OraSure Technologies by 2.5% in the 2nd quarter. AXA S.A. now owns 161,614 shares of the medical instruments supplier’s stock worth $688,000 after buying an additional 3,997 shares during the last quarter. SG Americas Securities LLC boosted its holdings in OraSure Technologies by 46.4% in the second quarter. SG Americas Securities LLC now owns 17,125 shares of the medical instruments supplier’s stock worth $73,000 after acquiring an additional 5,431 shares in the last quarter. Koss Olinger Consulting LLC grew its stake in shares of OraSure Technologies by 9.4% in the third quarter. Koss Olinger Consulting LLC now owns 83,977 shares of the medical instruments supplier’s stock worth $359,000 after acquiring an additional 7,247 shares during the last quarter. Atom Investors LP bought a new position in shares of OraSure Technologies during the third quarter valued at $49,000. Finally, SkyView Investment Advisors LLC increased its holdings in shares of OraSure Technologies by 100.0% during the second quarter. SkyView Investment Advisors LLC now owns 24,000 shares of the medical instruments supplier’s stock valued at $102,000 after acquiring an additional 12,000 shares in the last quarter. Institutional investors own 93.50% of the company’s stock.

OraSure Technologies Trading Down 0.8 %

OSUR stock opened at $3.84 on Friday. The stock’s 50 day simple moving average is $4.05 and its 200 day simple moving average is $4.27. OraSure Technologies, Inc. has a 12-month low of $3.72 and a 12-month high of $8.45. The stock has a market capitalization of $286.43 million, a PE ratio of 25.60 and a beta of 0.03.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. The firm had revenue of $39.92 million for the quarter, compared to the consensus estimate of $38.97 million. During the same period in the prior year, the company posted $0.27 earnings per share. The company’s quarterly revenue was down 55.2% on a year-over-year basis. On average, research analysts predict that OraSure Technologies, Inc. will post -0.09 earnings per share for the current year.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Friday, October 4th.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.